Product image of Iluvien (Fluocinolone Acetonide) supplied by GNH India

Iluvien

Active Ingredient:
Fluocinolone Acetonide
Origin:
EU

Iluvien (Fluocinolone Acetonide)

Fluocinolone Acetonide, the active ingredient in Iluvien, is a glucocorticoid presented as a 0.19 mg sustained‑release intravitreal implant for intravitreal use. It treats chronic diabetic macular edema in adults, delivering long‑term anti‑inflammatory action directly to the retina. The implant provides continuous low‑dose release over up to 36 months, reducing the need for frequent injections.

GNH India supplies Iluvien as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, ophthalmology clinics, and procurement teams worldwide, ensuring reliable global distribution and regulatory compliance.

Manufacturer / TM Owner

Alimera Sciences Europe Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Iluvien, a sustained‑release glucocorticoid implant, is indicated for chronic diabetic macular edema, a condition characterized by retinal swelling due to diabetes.

  • Chronic diabetic macular edema: reduces retinal fluid accumulation and improves visual acuity in patients with persistent disease despite other therapies.
  • Diabetic macular edema unresponsive to anti‑VEGF therapy: provides an alternative corticosteroid option for eyes that have not responded adequately to anti‑VEGF agents.
  • Diabetic macular edema in pseudophakic eyes: offers benefit without adding cataract risk in patients who have already undergone lens replacement.

How It Works

  • Fluocinolone acetonide binds intracellular glucocorticoid receptors in ocular tissues, altering gene transcription to suppress inflammatory cytokines, decrease vascular permeability, and inhibit neovascularization. The sustained‑release implant maintains therapeutic drug levels in the vitreous cavity for up to three years, providing continuous anti‑inflammatory and anti‑edematous effects.

Side Effects

Iluvien may be associated with ocular and systemic adverse reactions, which are categorized by frequency.

Common Side Effects

  • Increased intraocular pressure: may require topical or surgical management.
  • Cataract formation: accelerated lens opacity in phakic eyes.
  • Vitreous hemorrhage: bleeding within the vitreous cavity.
  • Ocular inflammation: mild anterior chamber reaction.
  • Floaters: perception of moving spots in vision.
  • Transient reduction in visual acuity: short‑term worsening after implantation.

Serious or Rare Side Effects

  • Endophthalmitis: severe intraocular infection requiring urgent treatment.
  • Retinal detachment: separation of retinal layers that can threaten vision.
  • Implant migration: displacement of the device to an unintended ocular location.
  • Severe ocular hypertension: pressure elevation unresponsive to medication.
  • Optic nerve damage: rare ischemic injury.
  • Systemic corticosteroid effects: possible hyperglycemia or adrenal suppression in susceptible patients.

Precautions & Warnings

Prior to Iluvien implantation, clinicians should assess ocular health and monitor for potential complications.

  • Monitor intraocular pressure: schedule regular tonometry checks.
  • Assess cataract status: evaluate lens clarity before and after treatment.
  • Screen for ocular infection: avoid implantation in the presence of active infection.
  • Use caution in glaucoma patients: heightened risk of pressure spikes.
  • Evaluate systemic steroid exposure: consider cumulative corticosteroid load.
  • Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Iluvien may interact with other ocular or systemic therapies that influence inflammation or intraocular pressure.

Major Interactions (Avoid)

  • Concomitant intraocular corticosteroids: risk of additive pressure elevation and cataract formation.
  • Systemic immunosuppressants: increased susceptibility to ocular infection.

Moderate Interactions (Monitor Closely)

  • Topical ocular NSAIDs: may potentiate intraocular pressure changes.
  • Systemic CYP3A4 inducers: could modestly reduce local drug exposure.
  • Anticoagulants: may increase risk of intraocular hemorrhage during implantation.
  • Other intraocular devices: assess compatibility to prevent mechanical interference.

Frequently Asked Questions

Iluvien is a sustained‑release intravitreal implant that delivers fluocinolone acetonide directly to the eye. It is approved for the treatment of chronic diabetic macular edema, helping to reduce retinal swelling and improve visual acuity in patients whose condition persists despite other therapies.

Fluocinolone acetonide binds to glucocorticoid receptors within ocular cells, modulating gene transcription to suppress inflammatory mediators, lower vascular permeability, and inhibit abnormal blood‑vessel growth. The implant releases a low, steady dose over several years, maintaining these anti‑inflammatory effects locally.

The dose of Iluvien is determined by the prescribing ophthalmologist. The product is supplied as a single‑use 0.19 mg intravitreal implant that is surgically placed in the vitreous cavity, and the frequency of re‑implantation is based on clinical response and monitoring.

The safety of Iluvien in pregnancy and lactation has not been established. Because fluocinolone acetonide is a corticosteroid, the potential risks to the fetus or infant should be weighed against the therapeutic benefits, and treatment decisions should involve the prescribing physician.

To request Iluvien, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Iluvien offers a long‑acting corticosteroid option that can reduce the need for frequent intravitreal injections, unlike anti‑VEGF agents that often require monthly dosing. It is particularly useful for patients who have an inadequate response to anti‑VEGF therapy, though it carries a different risk profile, such as higher rates of intraocular pressure rise and cataract formation.

Iluvien should be stored at ambient temperature, below 25 °C, in its original sealed packaging. Protect the implant from moisture and direct sunlight. Do not expose it to extreme temperatures or mechanical shock before surgical implantation.

Iluvien is implanted surgically into the vitreous cavity of the eye by a qualified ophthalmic surgeon. The procedure involves a pars plana insertion of the 0.19 mg sustained‑release implant, after which the device remains in place, continuously releasing fluocinolone acetonide for up to 36 months.

The most serious risks include severe intraocular hypertension that may be resistant to medication, cataract progression requiring surgery, endophthalmitis (a serious eye infection), retinal detachment, and rare cases of implant migration. Patients should be monitored regularly for these complications.

Iluvien is contraindicated in eyes with active ocular infection, uncontrolled glaucoma, or a known hypersensitivity to fluocinolone acetonide or any component of the implant. It should also be avoided in patients who have had recent intraocular surgery or laser procedures unless cleared by the treating ophthalmologist.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Fluocinolone Acetonide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT